The study analyzed 205,065 first-time visits for ADHD and 933,455 first-time visits for anxiety from Jan. 1, 2020, through March 31, 2023, to assess the medication prescribing rates for telehealth versus in-person visits.
Stimulants are considered a first-line treatment for ADHD and are classified as controlled substances. They are not typically prescribed for anxiety, which was used as a comparison point.
The study found that:
- Prescribing rates for ADHD medication within 30 days of initial diagnosis are similar for both telehealth and in-person office visits.
- Anti-anxiety medication prescriptions within 30 days of a telehealth or in-person visit were also found to be similar; however, anti-anxiety medications were prescribed less often than ADHD medications, according to the June 27 study.
This comes at a time when the Drug Enforcement Agency tried to propose a rule that would require physicians to conduct an in-person evaluation prior to prescribing controlled substances via telemedicine, though after significant pushback, the DEA granted a temporary extension allowing physicians to prescribe controlled substances virtually without an in-person evaluation.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
